Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets + Dapagliflozin tablets and Metformin HCl extended-release tablets
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes Mellitus (T2DM)
Conditions
Type 2 Diabetes Mellitus (T2DM)
Trial Timeline
Mar 15, 2024 → Jun 30, 2025
NCT ID
NCT06327815About Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets + Dapagliflozin tablets and Metformin HCl extended-release tablets
Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets + Dapagliflozin tablets and Metformin HCl extended-release tablets is a approved stage product being developed by AstraZeneca for Type 2 Diabetes Mellitus (T2DM). The current trial status is completed. This product is registered under clinical trial identifier NCT06327815. Target conditions include Type 2 Diabetes Mellitus (T2DM).
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06327815 | Approved | Completed |
Competing Products
20 competing products in Type 2 Diabetes Mellitus (T2DM)